Whiplash injury
Also known as: Trauma, Injury, Destruction, Traumatic
Methodology & AI Transparency ⓘ
Whiplash injury Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Whiplash injury (also termed Trauma or Injury) (ICD-10-CM S13.4XXA), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Whiplash injury (S13.4XXA: pairing lifestyle nutrition/exercise) paired with baseline and interval 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) assessment.
- 2 Real-world patient consensus: Synonyms for Whiplash injury (S13.4XXA): Trauma, Injury, Destruction (Preventive & Labs).
- 3 Typical cash cost range: Workup highlights for Whiplash injury (S13.4XXA): evidence-based risk stratification in Whiplash injury (S13.4XXA: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Follow-up benchmark in Whiplash injury: maintaining 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) within 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (S13.4XXA).
Ask our AI Specialists anything about Whiplash injury
What Is Whiplash injury?
For patients presenting with Whiplash injury (also termed Trauma or Injury) (ICD-10-CM S13.4XXA), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Whiplash injury (S13.4XXA: pairing lifestyle nutrition/exercise) paired with baseline and interval 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Whiplash injury (code S13.4XXA) is systemic inflammation [Whiplash injury S13.4XXA], which Preventive Screening & Blood Biomarkers clinicians address while surveilling 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (S13.4XXA)).
Common Symptoms & Clinical Signs
- • Presentation of Whiplash injury (S13.4XXA): proactive annual or in Whiplash injury (S13.4XXA: semiannual health checkup)
- • Secondary Whiplash injury clinical sign: follow-up of borderline in Whiplash injury (S13.4XXA: laboratory values before)
- • Symptom flares in Whiplash injury correlating with 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) deviation outside 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (S13.4XXA)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Whiplash injury (S13.4XXA: pairing lifestyle nutrition/exercise) evaluation (S13.4XXA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Whiplash injury Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | S13.4XXA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Whiplash injury (S13.4XXA: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (S13.4XXA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Whiplash injury (S13.4XXA: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (S13.4XXA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Whiplash injury (S13.4XXA: eGFR Baseline) | Within optimal preventive reference intervals (S13.4XXA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Whiplash injury
Treatment selection for Whiplash injury depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Whiplash injury)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Modeling Disease Progression and Placebo Response in Huntington Disease: Insights We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates. Neurology • 2025-05-27 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40315394 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants. Annals of clinical and translational neurology • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42117361 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with In C5i-experienced patients, increased Hb levels correlated with improvement in FACIT-Fatigue scores (R = 0.48); in C5i-naive patients, increased Hb (R = 0.42) and decreased LDH (R = -0.53) (all P < .001) correlated with... Blood advances • 2025-04-22 • Phase III Randomized Trial | N = 40 | 82/100 | PMID 39774762 ↗ |
Whiplash injury Patient Community & “People Like Me” Threads
Filter Whiplash injury community threads and patient logs by age, biological sex, dosage, and treatment duration.